Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2015 - 2023)

Cartesian Therapeutics (RNAC) has 5 years of Long-Term Debt Repayments data on file, last reported at $24.9 million in Q3 2023.

• On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $24.9 million in Q3 2023; TTM through Dec 2024 was $24.9 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $27.5 million, changed N/A from the prior year.
• Long-Term Debt Repayments for Q3 2023 stood at $24.9 million, up from $15.1 million in the prior quarter.
• Over the last five years, Long-Term Debt Repayments for RNAC reached as high as $24.9 million in Q3 2023 and fell as low as $700000.0 in Q3 2019.
• Historically, Long-Term Debt Repayments has averaged $7.8 million across 3 years, with a median of $2.1 million in 2019.
• On a YoY basis, Long-Term Debt Repayments climbed as much as 2059.0% in 2020 and fell as far as 2059.0% in 2020.
• Year by year, Long-Term Debt Repayments stood at $2.1 million in 2019, then jumped by 619.67% to $15.1 million in 2020, then surged by 64.57% to $24.9 million in 2023.
• Per Business Quant data, the three most recent Long-Term Debt Repayments figures were $24.9 million in Q3 2023, $15.1 million in Q3 2020, and $2.1 million in Q2 2020.